Order
 
HOME
 
Alzheimers
 
Piracetam
 
Idebenone
 
 
 
 
 
 
 
 
 
 
 
 
 
 

































 

Neuroprotection by deprenyl and related compounds

Maruyama W, Naoi M

Department of Basic Gerontology,
National Institute for Longevity Sciences  Obu, Japan.
maruyama@nils.go.jp
Mech Ageing Dev 1999 Nov; 111(2-3):189-200

ABSTRACT

There is an increasing number of data by in vitro and in vivo experiments, indicating that (-)-deprenyl is neuroprotective to dopamine neurons, even though detailed mechanism remains to be clarified.  In this paper neuroprotection by (-)-deprenyl and structurally related compounds was examined in concern with the suppression of apoptosis induced by a reactive oxygen species, peroxynitrite generated from SIN-1.  The apoptotic DNA damage was quantitatively determined using dopaminergic SH-SYSY cells and by a single cell gel electrophoresis (comet) assay.  DNA damage induced by peroxynitrite was proved to be apoptotic by prevention of the damage by cycloheximide or actinomycin-D. (-)-Deprenyl and other propargylamines protected the cells from apoptosis in a dose-dependent way. (-)-Deprenyl protected the cells even after it was washed out, suggesting that it may initiate the intracellular process to repress the apoptotic death program.  The study on the structure-activity relationship of (-)-deprenyl analogues revealed that a N-propargyl residue with adequate size of hydrophobic structure is essentially required for the anti-apoptotic activity.  These results suggest that (-)-deprenyl and related compounds may protect neurons from apoptosis and be applicable to delay the deterioration of neurons during advancing ageing and in neurodegenerative disorders.


| Home | Order |
  • Deprenyl  in the treatment of Alzheimer's disease
  • Deprenyl  MAO-B inhibitors in the treatment of Alzheimer's disease
  • Deprenyl  for Alzheimer's disease
  • Deprenyl  stimulates biosynthesis of cytokines interleukin-1 & 6
  • Deprenyl  and age-related decline of the striatal dopaminergic system
  • Deprenyl  improves memory in amnesic Alzheimer's patients
  • Deprenyl  treatment of behavioral symptoms of Alzheimer's disease
  • Deprenyl   increases life span in Parkinson's patients
  • Deprenyl   possible mechanisms of action in Parkinson's disease
  • Deprenyl   effect on arm movement in early Parkinson's
  • Deprenyl   effect on cognitive functions in early Parkinson's 
  • Deprenyl   possible mechanisms of action in Parkinson's
  • Deprenyl   depression in Parkinson's disease
  • Deprenyl   improves visuo-motor control in early Parkinsonism
  • Deprenyl   management of early Parkinson's disease
  • Deprenyl   delays the onset of disability in Parkinsonian patients
  • Deprenyl   and tocopherol antioxidative therapy of Parkinsonism
  • Deprenyl   treatment and death of nigral neurons in Parkinson's disease.
  • Deprenyl   rationale for deprenyl medication in Parkinson's disease
  • Deprenyl   and levodopa in Parkinson's disease
  • Deprenyl   is an MAO-B inhibitor
  • Deprenyl   facilitates neuronal growth without inhibiting monoamine oxidase
  • Deprenyl   pharmacology
  • Deprenyl   biochemical actions
  • Deprenyl   effect of MAO-B inhibitors on MPP+ toxicity
  • Deprenyl   the history of its development
  • Deprenyl   protects neurons against neurotoxins
  • Deprenyl   in neurodegenerative disorders
  • Deprenyl   enhances the release of dopamine
  • Deprenyl   plus L-phenylalanine in the treatment of depression
  • Deprenyl   in the treatment-resistant of older depressive patients
  • Deprenyl   effects in atypical depressives
  • Deprenyl   up-regulates superoxide dismutase and catalase
  • Deprenyl   immunostimulant
  • Deprenyl   pharmacology
  • Deprenyl   effect on rat longevity and sexual acitivity
  • Deprenyl   effects of experimental cocaine administration
  • Deprenyl   effects on longevity in animals
  • Deprenyl   effects on subjective ratings of cocaine-induced euphoria
  • Deprenyl   increases the life span in Fischer rats
  • Deprenyl   effects on short term memory in young and aged dogs
  • Deprenyl   the facilitation of dopaminergic activity in the aged brain
  • Deprenyl   fluoxetine (Prozac) and deprenyl
  • Deprenyl   improves cardiac sympathetic terminal function in heart failure
  • Deprenyl   effect on dopamine concentration in the striatum of a primate
  • Deprenyl   a review of the pharmacology
  • Deprenyl   restores IGF-1 levels to young levels
  • Deprenyl   prolongs life in elderly dogs
  • Deprenyl   past, present, and future
  • Deprenyl   relevance to humans
  • Deprenyl   responses of forebrain neurons to deprenyl
  • Deprenyl   protects neurons from glutamate toxicity
  • Deprenyl   nitric oxide production and dilation of cerebral blood vessels
  • Deprenyl   modulates the decline of the striatal dopaminergic system
  • Deprenyl   inhibits tumor growth in rats with mammary tumors
  • Deprenyl   a catecholaminergic activity enhancer in the brain
  • Deprenyl   releases coupling in the catecholaminergic neurons
  • Deprenyl   clinical potential in neurologic and psychiatric disorders
  • Deprenyl   protects human dopaminergic neuroblastoma cells
  • Deprenyl   nitric oxide production and dilation of cerebral blood vessels
  • Deprenyl   assessing the effects of deprenyl on longevity of animals
  • Deprenyl   effects on cocaine-induced euphoria
  • Deprenyl   effects on response to experimental cocaine administration  
  • Deprenyl   Are metabolites of deprenyl useful or harmful?
  • Deprenyl   is devoid of amphetamine-like effects
  • Deprenyl   treated rats lived beyond the known maximum lifespan
  • Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6
  • Deprenyl   pharmacological basis of the beneficial effects
  • Deprenyl   modulates the decline of the dopamineric system